Leerink analyst Daina Graybosch downgraded iTeos Therapeutics (ITOS) to Market Perform from Outperform with a $9 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth
- iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended
- iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan
- iTeos Therapeutics Ends Collaboration with GSK
- GSK, iTeos ending development program for belrestotug